BioSpace News Archive

Cocrystal Pharma, Inc. announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A.

Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from its Phase 4, open-label clinical trial of VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in the head and neck region in adults (N=31).

Laxxon Medical announced today its attendance at the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.

CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland.

Sera Prognostics Inc. today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced that two abstracts have been accepted for poster presentations for the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held December 5 - 9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 1515.

Napo Pharmaceuticals today announced that the abstract for More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.

DexCom, Inc. announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting 3 posters including two today at the 2023 San Antonio Breast Cancer Symposium® at Henry B. Gonzalez Convention Center, San Antonio, TX.

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure.